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elp deﬁne the optimal drug exposure associated with treat-
ent efﬁcacy. The analyses of data from experimental
odels with different antifungal drug classes have identi-
ed distinct pharmacodynamic characteristics. Results from
hese models have been useful for deﬁning the relationship
etween antifungal exposures and efﬁcacy. More recently
linical data has become available allowing similar inves-
igation. These results of these studies have been similar
o those from experimental models and have cemented the
linical signiﬁcance of these pharmacodynamic concepts.
he analyses have been shown to be helpful for the design
f antifungal dosing intervals, choice of optimal dose levels,
herapeutic drug monitoring, and the development of sus-
eptibility breakpoints. Most of these preclinical and clinical
tudies have targeted therapeutic efﬁcacy against Candida
pecies. More recent studies have also considered other fun-
al pathogens and have begun to investigate the role of
nifungal pharmacodynamics and drug resistance develop-
ent. Although there remain many unanswered questions
egarding antifungal pharmacodynamics, available data sug-
est usefulness in the application of pharmacodynamics to
elp guide antifungal therapy.
oi:10.1016/j.ijid.2008.05.071
2.003
ew Generation Triazoles: What Do They Offer and When
o We Need Them?
.C. Sorrell
University of Sydney, Westmead, Australia
oriconazole and posaconazole are the latest triazole drugs
o be marketed. Voriconazole was developed from ﬂucona-
ole by substituting a ﬂuoropyrimidine ring for one of the
zole groups to enhance the spectrum (to include Can-
ida krusei, ﬂuconazole-resistant C. glabrata, Aspergillus
pp, some Fusarium strains, Scedosporium apiospermum and
imorphic fungi such as Histoplasma capsulatum) and adding
he a-methyl group to provide fungicidal activity against
spergillus spp. in particular. Posaconazole is structurally
erived from itraconazole, with ﬂuorine replacing chlorine
ubstituents in the phenyl ring and hydroxylation of the tria-
olone side chain. These modiﬁcations enhance the potency
nd spectrum of antifungal activity to include the additional
pecies covered by voriconazole with the exception of Fusar-
um and in addition, the zygomycetes.
Randomised controlled clinical trials (RCTs) have iden-
iﬁed that voriconazole is the treatment of choice for
nvasive aspergillosis in the immunosuppressed. Efﬁcacy
as been demonstrated in candidiasis (including against
mall numbers of ﬂuconazole-resistant Candida infections),
n fusariosis, cryptococcosis and infections where cheaper
gents such as ﬂuconazole would be preferred. The major
rawbacks to replacing ﬂuconazole with voriconazole are
ts cost, adverse effects including a small incidence of
hotosensitivity, signiﬁcant drug interactions, and pharma-
okinetic issues, which may be resolved by therapeutic drug
onitoring in some settings.
Posaconazole has been subject to RCTs of its use
n prophylaxis against fungal infections in recipients of
aematopoietic stem cell transplants where, despite some
d
m
r
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esign ﬂaws, it has performed better than the comparator
egimen, and in HIV-associated oro-pharyngeal candidiasis.
t has been used as salvage therapy in other settings. The
ain drawbacks to widespread use of posaconazole include
ost, the lack of an intravenous formulation, reduced
ioavailability in the absence of food and lack of RCTs of
ts therapeutic use.
Conﬁrmation of improved clinical outcomes from the use
f either agent in combination therapy is yet to be obtained.
oi:10.1016/j.ijid.2008.05.072
2.004
nderstanding the Similarities and Differences of Existing
nd Emerging Echinocandins
.A. Slavin
Peter MacCallum Cancer Centre, Melbourne, Australia
he echinocandins, comprising caspofungin, micafungin and
nidulafungin, inhibit beta-(1,3)-glucan, Glucan is found in
ungal cell walls but not mammalian cells. As large highly
rotein bound molecules, none are orally bioavailable or
chieve levels in the CSF. The spectrum is consistent across
ll three agents with fungicidal activity against Candida, and
ungistatic activity against Aspergillus. The echinocandins
re not active against Cryptococcus,Scedosporium prolif-
cans or Zygomycetes. All are fungicidal against Candida
pecies although MIC90s vary slightly between agents with
he lowest MIC90s seen with anidulafungin, then micafungin,
nd caspofungin. However, it is not clear if these differ-
nces are clinically relevant. All have higher MIC90s for C.
arapsilosis, C. guilliermondii and C. lusitaniae compared
o other Candida spp. Although C. parapsilosis remains sus-
eptible despite a higher MIC90, resistance has emerged on
reatment. All may rarely cause histamine release with pru-
itis, rash and swelling. The differences between the agents
re shown in the table below:
oi:10.1016/j.ijid.2008.05.073
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3.001
pidemiology of EV71 Outbreaks in the Region in the Past
ecade
. Kiyu1,∗, J. Cardosa2, K. Mohd-Noh1, R. Matbah1, C.H.
oi 1
Sarawak Health Department, Kuching, Malaysia
Institute of Health and Community Medicine, Universiti
alaysia Sarawak, Kuching, Malaysia
FMD: Current Knowledge and Challenges for Malaysia
nd the Asia Paciﬁc Region
Background: Hand, foot and mouth disease (HFMD), espe-
ially that caused by EV71 is an important re-emerging
isease in the Asia Paciﬁc region, with the potential to cause
assive outbreaks that can last for many months, and with
elatively high complications rates, and deaths.
Methods: A review of the ﬁrst-hand experiences gained
uring the control of the four major HFMD outbreaks in
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tor and development of transgenic mice susceptible to EV71
may provide new insights into the molecular basis of EV71
infection in the near future.13th International Congress on Infectious Diseases Abstracts
Sarawak was carried out. Relevant epidemiologic informa-
tion from outbreaks in a number of countries in the Asia
Paciﬁc region was also abstracted.
Results: From Sarawak, we learned that since 1997, EV71
outbreaks have occurred every 3 years. The shapes of the
epidemiological curves are inﬂuenced by social factors such
as the media and people’s movements during big public hol-
idays. EV71 is not the only virus associated with HFMD, but
only EV71 causes very large outbreaks and resulting com-
plications. The genogroups of the EV71 isolated during each
major outbreak are genetically distinct from each other. The
transmission of EV71 in a susceptible cohort is extremely
rapid with only 4—6 weeks between ﬁrst identiﬁcation of an
EV71 case in our sentinel clinics to peaking.From Singapore
we know that HEV71 transmission occurs mainly in places
where preschool children congregate, and public health
measures to control the spread of this virus should focus
on these places. The 1998 Taiwan outbreak showed that
HFMD spreads easily through contact leading to mostly symp-
tomatic cases in children and mostly asymptomatic cases in
adults. Proper surveillance systems works, showing trends
and the current circulating viruses, and predicting coming
outbreaks.
Conclusion: We need to identify the reservoirs of EV71 in
the inter-epidemic periods, and develop simple rapid diag-
nostic tests that can be used in the districts to differentiate
EV71 from CA16.
doi:10.1016/j.ijid.2008.05.074
Emergence of EV71 in the Asia Paciﬁc in the Last Decade
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13.002
Clinical Studies on EV71 Neurological Disease
M.H. Ooi1,∗, S.C. Wong2, T. Solomon3, M.J. Cardosa1
1 Universiti Malaysia Sarawak, Kota Samarahan, Malaysia
2 Sibu Hospital, Sibu, Malaysia
3 University of Liverpool, Liverpool, United Kingdom
Human enterovirus 71 (HEV71, family Picornaviridae, genus
Enterovirus) was ﬁrst described in 1974 after it was iso-
lated from children with neurological infection in California,
USA. Following the report, the virus has been linked to
a broad spectrum of neurological manifestations including
encephalitis, aseptic meningitis and poliomyelitis-like paral-
ysis. The neurotrophic virus is also associated with hand,
foot and mouth disease (HFMD), a common febrile rash ill-
ness caused by enterovirus, particularly Coxsackievirus A16.
Over the last 10 years frequent explosive outbreaks of HEV71
neurological disease have occurred in many parts of Asia
with dozens of fatalities. Brief duration of illness, subtle
clinical presentation, very late appearance of ominous signs
and unexpected fulminant pulmonary oedema and cardiac
dysfunction in previously healthy children with HFMD are the
hallmarks of fatal cases of neurological HEV71 infection. As
a result, HFMD, which is normally considered an innocuous
illness, has become a diagnostic and management challenge
to many clinicians in Asia. Clinicians are faced with several
important clinical questions when they are presented with
a child with HFMD:
dited Papers) e13
. How to distinguish a child with HEV71 infection from
CVA16?
. How to recognize children at risk of neurological infec-
tion and fatal pulmonary oedema?
. What therapeutic measures are best for a critically ill
child with HEV71 infection?
The results of a number of clinical studies that attempted
o resolve these clinical questions will be reviewed and pre-
ented in this talk. We shall also present new data from a
rospective study in Sarawak spanning 3 distinct outbreaks
f HEV71.
oi:10.1016/j.ijid.2008.05.075
3.003
ouse and Non-human Primate Models for EV71 Disease
. Shimizu
National Institute of Infectious Diseases, Tokyo, Japan
uring the ﬁnal stage of polio eradication in the Western
aciﬁc Region (WPR) in the late 1990s, there have been
arge outbreaks of hand, foot and mouth disease (HFMD)
ue to enterovirus 71 (EV71) associated with severe neu-
ological diseases. However, pathogenesis of EV71 infection
s still poorly understood, in part, due to limited animal
odels to study the neurovirulence of EV71. Immediately
fter the identiﬁcation of EV71 as one of most neurotropic
nteroviruses, a non-human primate model for EV71 dis-
ase had been established in the 1970s. In response to
ecent EV71-aassociated HFMD outbreaks in the WPR, we
ave extended this non-human primate model to study
he molecular basis of EV71 neurovirulence by using dif-
erent genotypes of ﬁeld EV71 isolates and genetically
odiﬁed EV71 mutants derived from infectious molecular
lones of EV71. By using the non-human primate model, we
ound that two major recent lineages of EV71 in the WPR,
enogroups B and C, are considered to be neurovirulent,
nd we have analyzed the attenuation determinants and
mmunogenicity of EV71 for further vaccine development.
he non-human primate model may provide more informa-
ion on EV71 pathogenesis than previous mouse infection
odels. However, mouse models, using young mice and/or
ouse-adapted EV71 variants, have been widely used to
tudy the in vivo phenotypes of EV71 due to the limited
vailability of non-human primates. Thus, we have recently
eveloped a novel mouse infection model using NOD/SCID
ice and a mouse adapted EV71 variant, and conﬁrmed the
resence of the same attenuation determinants of EV71 both
n non-human primate and mouse models. Although primate
nd mouse models would be still important to study the
athogenesis of EV71, identiﬁcation of the cellular recep-oi:10.1016/j.ijid.2008.05.076
